Trial Outcomes & Findings for Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (NCT NCT04269200)

Last Updated: 2025-12-23

Results Overview

To demonstrate the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in patients with newly diagnosed advanced or recurrent endometrial cancer

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE3

Target enrollment

805 participants

Primary outcome timeframe

At baseline, every 9 weeks (wks) up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months

Results posted on

2025-12-23

Participant Flow

Global Cohort: 875 patients screened across 179 centres in 22 countries; 718 were randomised. Results were reported for analysis of progression-free survival (PFS) (data cut-off \[DCO\]: 12 Apr 2023). China Cohort: 172 patients screened across 25 sites; 129 were randomized. Results were reported for analysis of PFS (DCO: 08 Jul 2024). In total, 805 patients were randomised; 718 to the Global cohort, 129 to the China cohort, with 42 patients overlapping and belonging to both cohorts.

It was planned that approximately 699 women from the Global cohort and 129 women from the China cohort, with newly diagnosed advanced or recurrent endometrial cancer, were to receive durvalumab/placebo in combination with platinum-based chemotherapy followed by maintenance durvalumab/placebo (same treatment as during chemotherapy phase) and olaparib/placebo in a 1:1:1 ratio.

Participant milestones

Participant milestones
Measure	SoC + Durvalumab Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	SoC + Durvalumab + Olaparib Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	Standard of Care (SoC) Platinum-based chemotherapy (paclitaxel and carboplatin) every 3 weeks (Q3W) for a maximum of 6 cycles with durvalumab placebo (intravenous \[IV\]) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) every 4 weeks (Q4W) and olaparib placebo (tablets) twice daily (bd) orally as maintenance treatment until disease progression.
Global Cohort STARTED	238	239	241
Global Cohort COMPLETED	159	170	147
Global Cohort NOT COMPLETED	79	69	94
China Cohort STARTED	43	42	44
China Cohort COMPLETED	29	24	30
China Cohort NOT COMPLETED	14	18	14

Reasons for withdrawal

Reasons for withdrawal
Measure	SoC + Durvalumab Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	SoC + Durvalumab + Olaparib Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	Standard of Care (SoC) Platinum-based chemotherapy (paclitaxel and carboplatin) every 3 weeks (Q3W) for a maximum of 6 cycles with durvalumab placebo (intravenous \[IV\]) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) every 4 weeks (Q4W) and olaparib placebo (tablets) twice daily (bd) orally as maintenance treatment until disease progression.
Global Cohort Death	54	49	72
Global Cohort Lost to Follow-up	0	2	0
Global Cohort Withdrawal by Subject	25	18	22
China Cohort Death	11	13	12
China Cohort Lost to Follow-up	1	1	0
China Cohort Withdrawal by Subject	2	4	2

Baseline Characteristics

The results are presented by Global cohort and by China cohort.

Baseline characteristics by cohort

PRIMARY outcome

Timeframe: At baseline, every 9 weeks (wks) up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months

Population: Full Analysis Set (FAS) consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 20 Apr 2022). China FAS includes all patients who were randomised at sites in China and Hong Kong.

Outcome measures

Outcome measures
Measure	Global Cohort - SoC n=241 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=238 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=239 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC n=44 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab n=43 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib n=42 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments	9.6 Months Interval 9.0 to 9.9	10.2 Months Interval 9.7 to 14.7	15.1 Months Interval 12.6 to 20.7	9.7 Months Interval 7.6 to 12.3	9.9 Months Interval 8.2 to 20.6	9.9 Months Interval 7.1 to 12.6

SECONDARY outcome

Timeframe: Survival assessed every 2 months after RECIST defined radiological progression; assessed through study completion, up to 83 months

To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of OS

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At baseline, every 9 to 18 wks, then every 12 wks until objective radiological disease progression. Assessments then per local practice every 12 wks until second progression. Assessed until 12Apr2023 DCO (08Jul2024 DCO for China cohort), up to 50 months

Population: FAS consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 20 Apr 2022). China FAS includes all patients who were randomised at sites in China and Hong Kong.

Outcome measures

Outcome measures
Measure	Global Cohort - SoC n=241 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=238 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=239 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC n=44 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab n=43 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib n=42 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Time From Randomisation to Second Progression or Death (PFS2) Based on Local Standard Clinical Practice	19.1 Months Interval 16.4 to 22.9	22.2 Months Interval 18.7 to Insufficient PFS2 events to estimate upper confidence limit.	NA Months Insufficient PFS2 events to estimate median and confidence limits.	24.2 Months Interval 15.5 to Insufficient PFS2 events to estimate upper confidence limit.	19.7 Months Interval 15.3 to Insufficient PFS2 events to estimate upper confidence limit.	15.3 Months Interval 12.7 to Insufficient PFS2 events to estimate upper confidence limit.

SECONDARY outcome

Timeframe: At baseline, every 9 to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months

Population: All participants with measurable disease at baseline were included in the analysis. FAS consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 20 Apr 2022). China FAS includes all patients who were randomised at sites in China and Hong Kong. Odds ratio only calculated for Global cohort (per statistical analysis plan \[SAP\]).

Outcome measures

Outcome measures
Measure	Global Cohort - SoC n=198 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=202 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=184 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC n=37 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab n=32 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib n=33 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Objective Response Rate (ORR) Based on Investigator Assessment	55.1 Percentage of participants	61.9 Percentage of participants	63.6 Percentage of participants	59.5 Percentage of participants	59.4 Percentage of participants	45.5 Percentage of participants

SECONDARY outcome

Timeframe: At baseline, every 9 wks up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO, up to 35 months

Population: All participants with confirmed response were included in the analysis. FAS consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 20 Apr 2022). This endpoint was not assessed in the China cohort as it was not prespecified in the statistical analysis plan (SAP).

Outcome measures

Outcome measures
Measure	Global Cohort - SoC n=109 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=125 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=117 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Duration of Response (DoR) Based on Investigator Assessment	7.7 Months Interval 5.1 to 13.5	13.1 Months Interval 6.0 to Insufficient DoR events to estimate upper confidence limit.	21.3 Months Interval 8.1 to 29.9	—	—	—

SECONDARY outcome

Timeframe: Time elapsed from randomisation to first subsequent therapy or death. Assessed every 12 wks following treatment discontinuation, through study completion (up to 83 months)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Time elapsed from randomisation to second subsequent therapy or death. Assessed every 12 wks following treatment discontinuation, through study completion (up to 83 months)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Time elapsed from randomisation to study treatment discontinuation or death. Assessed through study completion, up to 83 months

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: PK sampling performed on Day 85 pre-dose, Day 183 pre-dose, and 3 months after study treatment discontinuation (up to 36 months)

Population: The Overall Number of Participants Analyzed reflects the total number of patients included in the PK Analysis Set, which comprises those treated with durvalumab per protocol and with valid PK data. However, PK concentrations were excluded at the sample level if they do not meet protocol-defined criteria. While some patients may not have any valid samples due to these exclusions, they remain part of the analysis population set by definition.

To characterise the pharmacokinetics (PK) of durvalumab and durvalumab in combination with olaparib

Outcome measures

Outcome measures
Measure	Global Cohort - SoC n=204 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=213 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=36 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC n=35 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Serum Concentration of Durvalumab Day 85, pre-dose (Trough concentration)	203.133538 μg/mL Geometric Coefficient of Variation 32.6	196.218276 μg/mL Geometric Coefficient of Variation 31.7	183.414442 μg/mL Geometric Coefficient of Variation 32.7	NA μg/mL Geometric Coefficient of Variation NA As pre-specified in the Statistical Analysis Plan, three observations above the lower limit of quantification (LLOQ) are required as a minimum for a serum concentration to be summarised. Two observations above the LLOQ are presented as minimum and maximum with the other summary statistics as not calculated.	—	—
Serum Concentration of Durvalumab Day 183, pre-dose (Trough concentration)	265.575840 μg/mL Geometric Coefficient of Variation 39.6	236.315365 μg/mL Geometric Coefficient of Variation 38.0	—	NA μg/mL Geometric Coefficient of Variation NA As pre-specified in the Statistical Analysis Plan, three observations above the lower limit of quantification (LLOQ) are required as a minimum for a serum concentration to be summarised. Two observations above the LLOQ are presented as minimum and maximum with the other summary statistics as not calculated.	—	—
Serum Concentration of Durvalumab Follow-up 3-months (Last valid dose + 3 months)	27.977227 μg/mL Geometric Coefficient of Variation 104.4	14.031316 μg/mL Geometric Coefficient of Variation 206.8	33.310921 μg/mL Geometric Coefficient of Variation 43.0	11.252155 μg/mL Geometric Coefficient of Variation 1429.7	—	—

SECONDARY outcome

Timeframe: Immunogenicity sampling performed on Day 1 pre-dose, Day 85 pre-dose, Day 183 pre-dose, and 3 and 6 months after study treatment discontinuation (up to 39 months)

Population: ADA Analysis Set. This includes all patients who receive at least 1 dose of durvalumab and have non-missing baseline ADA and at least 1 post-baseline ADA result.

To characterise the immunogenicity of durvalumab and durvalumab in combination with olaparib

Outcome measures

Outcome measures
Measure	Global Cohort - SoC n=198 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=207 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=35 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC n=33 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Anti-drug Antibodies (ADA) to Durvalumab ADA positive post-baseline and positive at baseline	0 Number of participants	0 Number of participants	0 Number of participants	0 Number of participants	—	—
Anti-drug Antibodies (ADA) to Durvalumab Persistently positive	2 Number of participants	0 Number of participants	0 Number of participants	0 Number of participants	—	—
Anti-drug Antibodies (ADA) to Durvalumab Transiently positive	0 Number of participants	0 Number of participants	0 Number of participants	0 Number of participants	—	—
Anti-drug Antibodies (ADA) to Durvalumab Neutralising antibody positive at any visit	1 Number of participants	0 Number of participants	0 Number of participants	0 Number of participants	—	—
Anti-drug Antibodies (ADA) to Durvalumab ADA positive at baseline only	6 Number of participants	9 Number of participants	0 Number of participants	1 Number of participants	—	—
Anti-drug Antibodies (ADA) to Durvalumab ADA-positive at any visit (ADA prevalence)	8 Number of participants	9 Number of participants	0 Number of participants	1 Number of participants	—	—
Anti-drug Antibodies (ADA) to Durvalumab Treatment-emergent ADA-positive (ADA incidence)	2 Number of participants	0 Number of participants	0 Number of participants	0 Number of participants	—	—
Anti-drug Antibodies (ADA) to Durvalumab Treatment-boosted ADA	0 Number of participants	0 Number of participants	0 Number of participants	0 Number of participants	—	—
Anti-drug Antibodies (ADA) to Durvalumab Treatment-induced ADA (positive post-baseline only)	2 Number of participants	0 Number of participants	0 Number of participants	0 Number of participants	—	—

SECONDARY outcome

Timeframe: At baseline, every 3 wks until Wk 18, and every 4 wks until the second progression. Assessed until 12 Apr 2023 DCO, up to 35 months. The average treatment effect over the first 12 months after randomisation is presented.

Population: FAS consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 20 Apr 2022). All participants with a baseline and post baseline physical functioning score available were analysed. This endpoint was not assessed in the China cohort as it was not prespecified in the SAP.

To determine effects on symptoms, functioning, and overall health related quality of life (HRQoL) of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy alone in newly diagnosed advanced or recurrent endometrial cancer patients. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function.

Outcome measures

Outcome measures
Measure	Global Cohort - SoC n=187 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=190 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=199 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Change From Baseline in Physical Functioning Score of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients 30 (EORTC QLQ-C30)	-5.3 Score on a scale Standard Error 1.03	-3.6 Score on a scale Standard Error 1.02	-5.9 Score on a scale Standard Error 0.98	—	—	—

SECONDARY outcome

Population: FAS consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 20 Apr 2022). All participants with a baseline and post baseline global health status/QoL available were analysed. This endpoint was not assessed in the China cohort as it was not prespecified in the SAP.

To determine effects on symptoms, functioning, and overall HRQoL of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy alone in newly diagnosed advanced or recurrent endometrial cancer patients. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function.

Outcome measures

Outcome measures
Measure	Global Cohort - SoC n=187 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=190 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=199 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Change From Baseline in Global Health Status/QoL Score of the EORTC QLQ-C30	-2.8 Score on a scale Standard Error 0.93	-2.7 Score on a scale Standard Error 0.92	-3.6 Score on a scale Standard Error 0.88	—	—	—

Adverse Events

Global Cohort - SoC

Serious events: 73 serious events

Other events: 233 other events

Deaths: 82 deaths

Global Cohort - SoC + Durvalumab

Serious events: 73 serious events

Other events: 228 other events

Deaths: 65 deaths

Global Cohort - SoC + Durvalumab + Olaparib

Serious events: 85 serious events

Other events: 236 other events

Deaths: 52 deaths

China Cohort - SoC

Serious events: 14 serious events

Other events: 44 other events

Deaths: 12 deaths

China Cohort - SoC + Durvalumab

Serious events: 8 serious events

Other events: 41 other events

Deaths: 11 deaths

China Cohort - SoC + Durvalumab + Olaparib

Serious events: 19 serious events

Other events: 39 other events

Deaths: 14 deaths

Serious adverse events

Serious adverse events
Measure	Global Cohort - SoC n=236 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=235 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=238 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC n=44 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, participants without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab n=41 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, participants without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib n=41 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Blood and lymphatic system disorders Lymphadenitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Lung abscess	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Neutropenic infection	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Neutropenic sepsis	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Paracancerous pneumonia	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Pelvic infection	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Peritonitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Pneumonia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Pneumonia aspiration	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Pneumonia bacterial	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Pseudomembranous colitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Myelosuppression	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Psoas abscess	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Pyelonephritis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Retroperitoneal abscess	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Sepsis	1.3% 3/236 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/238 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Septic shock	0.85% 2/236 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Staphylococcal bacteraemia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Upper respiratory tract infection	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Urinary tract infection	2.1% 5/236 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.5% 6/238 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Urinary tract infection enterococcal	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Urosepsis	1.3% 3/236 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Neutropenia	1.3% 3/236 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/235 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.1% 5/238 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations West nile viral infection	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Fall	1.3% 3/236 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Gastrointestinal stoma complication	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Occult blood	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Gun shot wound	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Asthenia	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Humerus fracture	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Incisional hernia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Infusion related reaction	1.3% 3/236 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Death	0.85% 2/236 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Tendon rupture	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Alanine aminotransferase increased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Pancytopenia	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Amylase increased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Aspartate aminotransferase increased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Blood bilirubin increased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Creatinine renal clearance decreased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations International normalised ratio increased	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Liver function test abnormal	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Neutrophil count decreased	1.7% 4/236 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Cardiac disorders Arrhythmia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Platelet count decreased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations White blood cell count decreased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Adult failure to thrive	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Dehydration	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Cardiac disorders Atrial fibrillation	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hypokalaemia	0.85% 2/236 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Cardiac disorders Cardiac arrest	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hyponatraemia	1.7% 4/236 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.1% 5/235 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Starvation ketoacidosis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Type 1 diabetes mellitus	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Chondrocalcinosis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Cardiac disorders Cardiogenic shock	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Eye disorders Cataract	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Myositis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Pathological fracture	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma of colon	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal adenoma	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive breast carcinoma	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Cardiac disorders Left ventricular failure	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Cerebral haemorrhage	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Cerebrovascular accident	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Dizziness	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Dyskinesia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Encephalopathy	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Ischaemic cerebral infarction	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Anaemia	4.2% 10/236 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.7% 16/238 • Number of events 33 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Cardiac disorders Myocardial infarction	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Ischaemic stroke	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Meralgia paraesthetica	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Myxoedema coma	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Peripheral motor neuropathy	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Presyncope	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Secondary cerebellar degeneration	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Speech disorder	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Cardiac disorders Sinus tachycardia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Spinal cord compression	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Syncope	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Transient ischaemic attack	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Tremor	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Psychiatric disorders Completed suicide	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Psychiatric disorders Delirium	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Psychiatric disorders Depression	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Acute kidney injury	0.85% 2/236 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Cystitis noninfective	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Hydronephrosis	0.85% 2/236 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Nephrolithiasis	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Renal failure	0.85% 2/236 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Renal infarct	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Ureteric obstruction	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Urinary bladder haemorrhage	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Urinary retention	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Urinary tract obstruction	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Reproductive system and breast disorders Female genital tract fistula	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Reproductive system and breast disorders Vaginal haemorrhage	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Ear and labyrinth disorders Vertigo	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	1.7% 4/236 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Dermatomyositis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Endocrine disorders Euthyroid sick syndrome	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Erythema multiforme	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Rash	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Rash maculo-papular	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Subcutaneous emphysema	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Urticaria	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Deep vein thrombosis	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Embolism	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Embolism venous	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Hypertension	0.42% 1/236 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Hypotension	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Lymphoedema	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Orthostatic hypotension	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Peripheral artery thrombosis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Thrombophlebitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Thrombosis	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Venous thrombosis limb	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Endocrine disorders Secondary adrenocortical insufficiency	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Aplasia pure red cell	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Eye disorders Retinal detachment	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Abdominal hernia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Abdominal pain	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Abdominal pain lower	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Anal haemorrhage	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Ascites	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Autoimmune haemolytic anaemia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Chronic gastritis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Colitis	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Colonic fistula	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Constipation	1.3% 3/236 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Diarrhoea	1.7% 4/236 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Duodenal stenosis	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Duodenal ulcer perforation	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Duodenitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Febrile neutropenia	3.4% 8/236 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/235 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.9% 7/238 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Dysphagia	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Faecal vomiting	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Faecaloma	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Gastric perforation	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Ileus	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Intestinal obstruction	0.85% 2/236 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Nausea	0.85% 2/236 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/235 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Haemolytic anaemia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Subileus	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Vomiting	0.85% 2/236 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.1% 5/235 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Fatigue	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders General physical health deterioration	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Hyperplasia	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Immune thrombocytopenia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Malaise	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Multiple organ dysfunction syndrome	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Non-cardiac chest pain	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Oedema peripheral	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Pain	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Pyrexia	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Systemic inflammatory response syndrome	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Hepatobiliary disorders Cholecystitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Hepatobiliary disorders Hypertransaminasaemia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Hepatobiliary disorders Immune-mediated cholangitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Hepatobiliary disorders Immune-mediated hepatic disorder	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Hepatobiliary disorders Immune-mediated hepatitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Hepatobiliary disorders Portal hypertension	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Immune system disorders Anaphylactic reaction	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Immune system disorders Anaphylactic shock	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Immune system disorders Contrast media allergy	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Immune system disorders Drug hypersensitivity	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Abdominal infection	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Leukopenia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Abscess limb	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Appendicitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Covid-19	1.3% 3/236 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/238 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Covid-19 pneumonia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Cellulitis	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Cholecystitis infective	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Gastroenteritis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Hepatitis c	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Herpes virus infection	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Intervertebral discitis	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased

Other adverse events

Other adverse events
Measure	Global Cohort - SoC n=236 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab n=235 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	Global Cohort - SoC + Durvalumab + Olaparib n=238 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC n=44 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, participants without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab n=41 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, participants without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	China Cohort - SoC + Durvalumab + Olaparib n=41 participants at risk Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.
Infections and infestations Pneumonia	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.1% 5/238 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Upper respiratory tract infection	3.4% 8/236 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/235 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.6% 11/238 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	15.9% 7/44 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Urinary tract infection	19.9% 47/236 • Number of events 65 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.6% 32/235 • Number of events 62 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	19.3% 46/238 • Number of events 67 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	18.2% 8/44 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Neutropenia	12.7% 30/236 • Number of events 48 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.5% 34/235 • Number of events 61 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	19.7% 47/238 • Number of events 85 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Fall	4.2% 10/236 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.0% 14/235 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.3% 15/238 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Injury, poisoning and procedural complications Infusion related reaction	9.3% 22/236 • Number of events 28 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.0% 14/235 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.0% 12/238 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Alanine aminotransferase increased	7.6% 18/236 • Number of events 24 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.8% 30/235 • Number of events 37 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.6% 30/238 • Number of events 41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	38.6% 17/44 • Number of events 33 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	39.0% 16/41 • Number of events 28 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	26.8% 11/41 • Number of events 22 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Aspartate aminotransferase increased	7.2% 17/236 • Number of events 26 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.4% 22/235 • Number of events 26 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	8.4% 20/238 • Number of events 25 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	38.6% 17/44 • Number of events 35 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	31.7% 13/41 • Number of events 24 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	34.1% 14/41 • Number of events 26 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Bile acids increased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Blood alkaline phosphatase increased	2.5% 6/236 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.7% 11/235 • Number of events 13 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.4% 8/238 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Blood bilirubin increased	1.7% 4/236 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/235 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.4% 5/44 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Blood creatinine increased	5.5% 13/236 • Number of events 20 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.3% 10/235 • Number of events 13 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	10.1% 24/238 • Number of events 42 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	24.4% 10/41 • Number of events 21 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Blood lactate dehydrogenase increased	5.9% 14/236 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.8% 9/235 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.4% 8/238 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Blood pressure increased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Blood thyroid stimulating hormone decreased	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/235 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Blood thyroid stimulating hormone increased	1.7% 4/236 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/235 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/238 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Thrombocytopenia	7.6% 18/236 • Number of events 30 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.8% 30/235 • Number of events 49 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.7% 35/238 • Number of events 70 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.4% 5/44 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Blood urea increased	1.7% 4/236 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/235 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Gamma-glutamyltransferase increased	5.1% 12/236 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.2% 17/235 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.3% 15/238 • Number of events 22 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	18.2% 8/44 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	22.0% 9/41 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Hepatic enzyme increased	2.1% 5/236 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/238 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Lipase increased	4.7% 11/236 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.0% 7/235 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.1% 5/238 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Lymphocyte count decreased	5.1% 12/236 • Number of events 21 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.7% 11/235 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.0% 12/238 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.6% 6/44 • Number of events 28 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 24 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	24.4% 10/41 • Number of events 32 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Neutrophil count decreased	25.4% 60/236 • Number of events 159 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	18.3% 43/235 • Number of events 105 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	21.0% 50/238 • Number of events 145 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	68.2% 30/44 • Number of events 138 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	73.2% 30/41 • Number of events 132 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	70.7% 29/41 • Number of events 149 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Neutrophil count increased	0.42% 1/236 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.85% 2/235 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Platelet count decreased	15.7% 37/236 • Number of events 73 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	15.3% 36/235 • Number of events 61 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	16.4% 39/238 • Number of events 71 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	47.7% 21/44 • Number of events 66 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	31.7% 13/41 • Number of events 24 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	36.6% 15/41 • Number of events 38 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Weight decreased	9.7% 23/236 • Number of events 28 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	8.5% 20/235 • Number of events 24 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.1% 17/238 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.6% 6/44 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	19.5% 8/41 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations Weight increased	3.0% 7/236 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.0% 7/235 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.2% 10/238 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.4% 5/44 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations White blood cell count decreased	16.9% 40/236 • Number of events 111 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.3% 29/235 • Number of events 67 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	16.0% 38/238 • Number of events 112 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	72.7% 32/44 • Number of events 159 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	73.2% 30/41 • Number of events 129 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	75.6% 31/41 • Number of events 161 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Investigations White blood cells urine positive	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Decreased appetite	19.5% 46/236 • Number of events 60 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.9% 42/235 • Number of events 57 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	23.1% 55/238 • Number of events 83 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	24.4% 10/41 • Number of events 18 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.43% 1/235 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hyperglycaemia	7.6% 18/236 • Number of events 25 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.4% 8/235 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.1% 17/238 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.4% 5/44 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hyperkalaemia	3.4% 8/236 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.1% 5/235 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.9% 7/238 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hyperlipidaemia	0.42% 1/236 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/235 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hypertriglyceridaemia	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	15.9% 7/44 • Number of events 13 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hyperuricaemia	1.3% 3/236 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/235 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	20.5% 9/44 • Number of events 18 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	19.5% 8/41 • Number of events 26 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hypoalbuminaemia	1.7% 4/236 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.8% 9/235 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.2% 10/238 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	22.0% 9/41 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hypocalcaemia	2.1% 5/236 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.1% 5/235 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.84% 2/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hypokalaemia	8.5% 20/236 • Number of events 37 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.1% 26/235 • Number of events 42 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.3% 27/238 • Number of events 49 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	25.0% 11/44 • Number of events 29 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	19.5% 8/41 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hypomagnesaemia	16.1% 38/236 • Number of events 53 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	16.2% 38/235 • Number of events 49 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	16.0% 38/238 • Number of events 66 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	20.5% 9/44 • Number of events 18 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Hyponatraemia	3.8% 9/236 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.4% 8/235 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.0% 12/238 • Number of events 22 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	22.0% 9/41 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Metabolism and nutrition disorders Type 2 diabetes mellitus	1.3% 3/236 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/235 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/238 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Arthralgia	24.6% 58/236 • Number of events 89 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	29.8% 70/235 • Number of events 112 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	24.4% 58/238 • Number of events 98 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.4% 5/44 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.6% 6/41 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Back pain	9.3% 22/236 • Number of events 33 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	8.1% 19/235 • Number of events 23 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.7% 35/238 • Number of events 39 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Bone pain	9.3% 22/236 • Number of events 25 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 16/235 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.6% 11/238 • Number of events 16 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Muscle spasms	5.1% 12/236 • Number of events 16 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.0% 7/235 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.4% 8/238 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Muscular weakness	6.4% 15/236 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.4% 15/235 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.5% 13/238 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Myalgia	18.6% 44/236 • Number of events 73 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.6% 32/235 • Number of events 47 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.6% 30/238 • Number of events 33 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Musculoskeletal and connective tissue disorders Pain in extremity	14.8% 35/236 • Number of events 42 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.2% 31/235 • Number of events 44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 29/238 • Number of events 38 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	22.7% 10/44 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.6% 6/41 • Number of events 13 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	22.0% 9/41 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Dizziness	12.7% 30/236 • Number of events 38 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.6% 32/235 • Number of events 37 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	16.8% 40/238 • Number of events 50 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Dysgeusia	11.0% 26/236 • Number of events 27 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	10.2% 24/235 • Number of events 28 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.3% 27/238 • Number of events 33 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Headache	14.8% 35/236 • Number of events 42 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.8% 30/235 • Number of events 34 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	16.4% 39/238 • Number of events 49 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Hypoaesthesia	5.1% 12/236 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.8% 9/235 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.3% 15/238 • Number of events 19 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	36.4% 16/44 • Number of events 24 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	43.9% 18/41 • Number of events 21 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Anaemia	51.3% 121/236 • Number of events 160 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	47.2% 111/235 • Number of events 168 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	59.2% 141/238 • Number of events 242 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	81.8% 36/44 • Number of events 101 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	68.3% 28/41 • Number of events 70 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	82.9% 34/41 • Number of events 88 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Neuropathy peripheral	28.0% 66/236 • Number of events 83 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	26.0% 61/235 • Number of events 69 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	25.2% 60/238 • Number of events 74 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Paraesthesia	4.2% 10/236 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.5% 13/235 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.5% 6/238 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Nervous system disorders Peripheral sensory neuropathy	28.0% 66/236 • Number of events 74 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	25.5% 60/235 • Number of events 69 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	25.2% 60/238 • Number of events 66 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Psychiatric disorders Insomnia	14.0% 33/236 • Number of events 35 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	10.2% 24/235 • Number of events 28 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 29/238 • Number of events 31 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.6% 6/44 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Cardiac disorders Supraventricular extrasystoles	0.00% 0/236 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Dysuria	5.1% 12/236 • Number of events 16 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.3% 10/235 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.2% 10/238 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Haematuria	4.7% 11/236 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/235 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.9% 7/238 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Renal and urinary disorders Pollakiuria	6.4% 15/236 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.3% 3/235 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.8% 9/238 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Cardiac disorders Ventricular extrasystoles	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/235 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/238 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Reproductive system and breast disorders Vaginal discharge	1.7% 4/236 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/235 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.5% 13/238 • Number of events 13 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Reproductive system and breast disorders Vaginal haemorrhage	5.5% 13/236 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.7% 11/235 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.8% 9/238 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Cough	10.6% 25/236 • Number of events 31 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.9% 35/235 • Number of events 38 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.4% 32/238 • Number of events 40 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	22.0% 9/41 • Number of events 11 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.6% 6/41 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Respiratory, thoracic and mediastinal disorders Dyspnoea	10.6% 25/236 • Number of events 29 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.5% 27/235 • Number of events 34 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 29/238 • Number of events 36 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Alopecia	50.0% 118/236 • Number of events 118 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	50.2% 118/235 • Number of events 122 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	50.8% 121/238 • Number of events 124 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	65.9% 29/44 • Number of events 29 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	48.8% 20/41 • Number of events 20 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	63.4% 26/41 • Number of events 26 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Pruritus	12.3% 29/236 • Number of events 41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	15.3% 36/235 • Number of events 42 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	15.5% 37/238 • Number of events 58 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.6% 6/44 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Rash	11.4% 27/236 • Number of events 32 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.4% 41/235 • Number of events 59 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	11.8% 28/238 • Number of events 38 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.6% 6/44 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	26.8% 11/41 • Number of events 33 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Skin and subcutaneous tissue disorders Rash maculo-papular	2.5% 6/236 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.5% 13/235 • Number of events 16 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.3% 15/238 • Number of events 23 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Vascular disorders Hypertension	5.5% 13/236 • Number of events 18 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.3% 10/235 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.5% 13/238 • Number of events 27 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Endocrine disorders Hyperthyroidism	1.7% 4/236 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.4% 15/235 • Number of events 16 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.5% 13/238 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.6% 6/41 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Endocrine disorders Hypothyroidism	3.4% 8/236 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	15.7% 37/235 • Number of events 44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.9% 33/238 • Number of events 42 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	24.4% 10/41 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Eye disorders Vision blurred	4.2% 10/236 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.1% 12/235 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.8% 9/238 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Abdominal distension	4.7% 11/236 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.3% 10/235 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.5% 13/238 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Abdominal pain	16.1% 38/236 • Number of events 39 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	16.2% 38/235 • Number of events 49 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	16.8% 40/238 • Number of events 53 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Abdominal pain lower	5.5% 13/236 • Number of events 13 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.4% 8/235 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.5% 6/238 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Abdominal pain upper	4.2% 10/236 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 16/235 • Number of events 17 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.9% 14/238 • Number of events 16 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Constipation	33.9% 80/236 • Number of events 102 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	26.8% 63/235 • Number of events 80 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	32.8% 78/238 • Number of events 105 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	22.7% 10/44 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	26.8% 11/41 • Number of events 18 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Diarrhoea	27.1% 64/236 • Number of events 101 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	31.5% 74/235 • Number of events 115 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	28.2% 67/238 • Number of events 114 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	22.7% 10/44 • Number of events 13 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.6% 6/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Dry mouth	2.1% 5/236 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.1% 5/235 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.8% 9/238 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Dyspepsia	7.6% 18/236 • Number of events 21 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.1% 12/235 • Number of events 13 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.2% 22/238 • Number of events 28 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Nausea	44.5% 105/236 • Number of events 182 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	40.4% 95/235 • Number of events 157 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	54.2% 129/238 • Number of events 237 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	40.9% 18/44 • Number of events 30 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	26.8% 11/41 • Number of events 30 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	43.9% 18/41 • Number of events 60 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Stomatitis	7.6% 18/236 • Number of events 24 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	8.1% 19/235 • Number of events 20 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	10.5% 25/238 • Number of events 31 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Toothache	0.42% 1/236 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.0% 7/235 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/238 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Gastrointestinal disorders Vomiting	17.8% 42/236 • Number of events 72 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	19.6% 46/235 • Number of events 73 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	25.6% 61/238 • Number of events 93 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	25.0% 11/44 • Number of events 15 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	26.8% 11/41 • Number of events 25 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	43.9% 18/41 • Number of events 37 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Asthenia	9.7% 23/236 • Number of events 34 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.4% 22/235 • Number of events 31 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	18.5% 44/238 • Number of events 72 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/44 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Chest discomfort	1.7% 4/236 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/235 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.1% 5/238 • Number of events 7 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Fatigue	36.9% 87/236 • Number of events 127 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	34.9% 82/235 • Number of events 101 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	39.1% 93/238 • Number of events 143 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.1% 4/44 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.6% 6/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Influenza like illness	3.4% 8/236 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.3% 10/235 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.8% 9/238 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.6% 6/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.9% 2/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Malaise	6.8% 16/236 • Number of events 21 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.0% 14/235 • Number of events 31 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.0% 12/238 • Number of events 18 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 5 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	22.0% 9/41 • Number of events 13 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Oedema peripheral	8.9% 21/236 • Number of events 23 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.3% 29/235 • Number of events 35 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.6% 30/238 • Number of events 37 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.00% 0/41 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Pain	3.8% 9/236 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.6% 6/235 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.2% 10/238 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	12.2% 5/41 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Peripheral swelling	2.5% 6/236 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	3.4% 8/235 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.2% 10/238 • Number of events 12 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.3% 1/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	2.4% 1/41 • Number of events 1 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
General disorders Pyrexia	7.6% 18/236 • Number of events 20 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	8.5% 20/235 • Number of events 27 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.7% 23/238 • Number of events 30 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 10 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Leukocytosis	1.3% 3/236 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	1.7% 4/235 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	0.42% 1/238 • Number of events 2 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	4.5% 2/44 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 3 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	7.3% 3/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Blood and lymphatic system disorders Leukopenia	3.8% 9/236 • Number of events 14 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	5.1% 12/235 • Number of events 25 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.3% 15/238 • Number of events 37 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	6.8% 3/44 • Number of events 6 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.6% 6/41 • Number of events 25 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	17.1% 7/41 • Number of events 22 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased
Infections and infestations Covid-19	12.3% 29/236 • Number of events 29 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	14.9% 35/235 • Number of events 36 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	18.5% 44/238 • Number of events 46 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	13.6% 6/44 • Number of events 8 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	19.5% 8/41 • Number of events 9 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased	9.8% 4/41 • Number of events 4 • Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months Deaths analysed in FAS; AEs analysed in all randomised patients who received study treatment. MedDRA 25.1 and 27.0 were used to code AEs in the Global and China cohorts, respectively. If the PT is not part of the MedDRA dictionary, the count is presented as zero. Otherwise, zero means that the term is part of the MedDRA version but no events were observed. Included in MedDRA 25.1 but not in MedDRA 27.0: Myxoedema coma Included in MedDRA 27.0 but not in MedDRA 25.1: Bile acids increased

Additional Information

Global Clinical Lead

AstraZeneca

Phone: 1-877-240-9479

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years after completion of the Study shall require the Sponsor's prior written consent.
Publication restrictions are in place

Restriction type: OTHER

Measure	SoC (Global Cohort & China Cohort) n=270 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	SoC + Durvalumab (Global Cohort & China Cohort) n=267 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.	SoC + Durvalumab + Olaparib (Global Cohort & China Cohort) n=268 Participants Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W. Following completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.	Total n=805 Participants Total of all reporting groups
Age, Continuous Global cohort	62.1 Years STANDARD_DEVIATION 10.36 • n=241 Participants • The results are presented by Global cohort and by China cohort.	63.3 Years STANDARD_DEVIATION 9.82 • n=238 Participants • The results are presented by Global cohort and by China cohort.	62.4 Years STANDARD_DEVIATION 9.90 • n=239 Participants • The results are presented by Global cohort and by China cohort.	62.6 Years STANDARD_DEVIATION 10.03 • n=718 Participants • The results are presented by Global cohort and by China cohort.
Age, Continuous China cohort	58.3 Years STANDARD_DEVIATION 8.73 • n=44 Participants • The results are presented by Global cohort and by China cohort.	57.6 Years STANDARD_DEVIATION 10.57 • n=43 Participants • The results are presented by Global cohort and by China cohort.	59.3 Years STANDARD_DEVIATION 8.41 • n=42 Participants • The results are presented by Global cohort and by China cohort.	58.4 Years STANDARD_DEVIATION 9.24 • n=129 Participants • The results are presented by Global cohort and by China cohort.
Age, Customized Global cohort · <65 years	124 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	122 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	135 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	381 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Age, Customized Global cohort · >=65 years	117 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	116 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	104 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	337 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Age, Customized China cohort · <65 years	35 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	30 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	30 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	95 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Age, Customized China cohort · >=65 years	9 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	13 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	12 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	34 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Sex/Gender, Customized Global cohort · Female	241 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	238 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	239 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	718 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Sex/Gender, Customized China cohort · Female	44 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	43 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	42 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	129 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Ethnicity (NIH/OMB) Global cohort · Hispanic or Latino	20 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	28 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	32 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	80 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Ethnicity (NIH/OMB) Global cohort · Not Hispanic or Latino	218 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	208 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	206 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	632 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Ethnicity (NIH/OMB) Global cohort · Unknown or Not Reported	3 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	2 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	1 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	6 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Ethnicity (NIH/OMB) China cohort · Hispanic or Latino	0 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Ethnicity (NIH/OMB) China cohort · Not Hispanic or Latino	44 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	43 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	42 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	129 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Ethnicity (NIH/OMB) China cohort · Unknown or Not Reported	0 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized Global cohort · White	143 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	136 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	133 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	412 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized Global cohort · Asian	73 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	72 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	70 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	215 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized Global cohort · Black or African American	10 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	11 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	14 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	35 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized Global cohort · Other	10 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	8 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	12 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	30 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized Global cohort · American Indian or Alaska Native	0 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	6 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	6 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	12 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized Global cohort · Native Hawaiian or Other Pacific Islander	2 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	1 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	3 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized Global cohort · Not reported	3 Participants n=241 Participants • The results are presented by Global cohort and by China cohort.	5 Participants n=238 Participants • The results are presented by Global cohort and by China cohort.	3 Participants n=239 Participants • The results are presented by Global cohort and by China cohort.	11 Participants n=718 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized China cohort · White	0 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized China cohort · Asian	44 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	43 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	42 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	129 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized China cohort · Black or African American	0 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized China cohort · Other	0 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized China cohort · American Indian or Alaska Native	0 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized China cohort · Native Hawaiian or Other Pacific Islander	0 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.
Race/Ethnicity, Customized China cohort · Not reported	0 Participants n=44 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=43 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=42 Participants • The results are presented by Global cohort and by China cohort.	0 Participants n=129 Participants • The results are presented by Global cohort and by China cohort.